Joel Randolph Hecht, MD, David Geffen School of Medicine, University of California Los Angeles (UCLA), reports on the Oncology Learning Network that, unfortunately, the findings from the SEQUOIA clinical trial of GEM-refractory pancreatic adenocarcinoma reveal no clinical benefit of adding pegilodecakin and FOLFOX as compared to FOLFOX alone. Dr. Hecht does offer an overview of recent studies and additional options for metastatic pancreatic cancer on the horizon.
Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. It is one of the most devastating of all cancers. Soon it will be leading the cause of cancer death in the United States. Although there have been some improvement—e.g. chemotherapy over the past decade—the immunotherapy breakthroughs haven’t benefited pancreatic cancer.
The SEQUOIA Study
In SEQUOIA, Eli Lilly and Armo Biosciences (acquired by Lilly) led a study to compare the efficacy of pegilodecakin in combination with FOLFOX versus FOLFOX (combo of chemo therapy drugs targeting bowel cancer) alone in participants with metastatic pancreatic cancer as measured by overall survival. Pegilodecakin is a cancer therapy being developed by ARMO Biosciences which Lilly acquired. Unfortunately, the primary endpoint, which was overall survival, was not significantly different between the two study arms with a median of 5.8 months in the experimental arm and 6.3 months in the control arm.
Visit Oncology Learning Network to listen to Dr. Hecht about this important study and the implications.
Joel Randolph Hecht, MD, David Geffen School of Medicine, University of California Los Angeles (UCLA)Source: Oncology Learning Network